Cancer Clinical Trails Expert assists Regen Biopharma, Inc. in addressing FDA questions regarding planned immunotherapy clinical trial for breast cancer (dCeflVax)

摘要

Assessment of Regen BioPharma Ine.'s planned Phase 1/ II clinical trials' safety concerns with Dr. SantoshKesariSAN DIEGO, CALIFORNIA; UNITED STATES - Regen BioPharma, Inc. announced the initiation of a collaboration with Dr.Santosh Kesari, Professor and Director of Neuro-oncology at University of California San Diego. The goals of the collaboration is to address questions posed by the FDA regarding Regn BioPharma Ine.'s planned Phase l/ll clinical trial assessing safety with signals of efficacy of the dCellVaxgene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability of clinical trial success.